Dentsply Sirona looks at long-term strategy as dental technology evolves
Dentsply Sirona, a global supplier of dental products and technologies, is focusing on its long-term strategy as dental technology evolves. The company's portfolio includes equipment, instruments, and consumable materials, balancing innovation, cost efficiency, and automation. Investors are keen to see how Dentsply Sirona manages its role in the global dental market, which relies on a mix of durable equipment and ongoing consumable sales.
PDS Health and Dentsply Sirona Surpass 5 Million CEREC Chairside Restorations
PDS Health and Dentsply Sirona have announced a significant milestone, with PDS Health practices completing over five million CEREC chairside restorations. This achievement highlights the widespread adoption of digital restorative technology in dental practices across the U.S., driven by PDS Health's extensive use of CAD/CAM technology with over 1,200 CEREC systems. The collaboration underscores a commitment to improving patient care through efficient, same-day treatments and enhanced workflow in restorative dentistry.
PDS Health Surpasses Five Million CEREC Chairside Restorations with Dentsply Sirona, Marking a Major Milestone in Scaled Digital Dentistry
PDS Health and Dentsply Sirona announced that PDS Health practices have completed over five million CEREC chairside restorations. This milestone highlights PDS Health's extensive adoption of digital dentistry, with over 1,200 CEREC systems, enabling same-day restorative care and improved patient experiences. The collaboration emphasizes a shared commitment to integrating advanced technologies for efficient, high-quality dental care at scale.
Form 4 Dentsply Sirona Inc For: 1 July By Investing.com
This article from Investing.com reports on the filing of Form 4 by Dentsply Sirona Inc. for activity on July 1st. The brief announcement indicates routine SEC disclosure for the company, marked by its stock symbol XRAY, which saw a 4.52% increase. The article itself contains minimal content beyond this transactional report.
[Form 4] DENTSPLY SIRONA Inc. Insider Trading Activity
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky reported an acquisition of 2,841.8303 phantom stock units as part of his deferred compensation. Each unit is economically equivalent to one share of common stock, valued at $10.56 per unit, and will be settled in common stock upon his departure from the board. This transaction is a non-cash, deferred compensation grant and not an open-market purchase or sale.
PDS Health Surpasses Five Million CEREC Chairside Restorations with Dentsply Sirona, Marking a Major Milestone in Scaled Digital Dentistry
PDS Health, in collaboration with Dentsply Sirona, has achieved a significant milestone by surpassing five million CEREC chairside restorations. This accomplishment highlights PDS Health's extensive adoption of digital dentistry solutions, with over 1,200 CEREC systems in its practices, enabling efficient, same-day restorative care for millions of patients. The partnership underscores a shared commitment to advancing digital technologies to improve workflow efficiency, clinical confidence, and the overall patient experience in restorative dentistry.
Does Dentsply Sirona’s (XRAY) Index Shift Recast Its Role in Dental Innovation Leadership?
Dentsply Sirona (XRAY) has shifted from large- to smaller-cap Russell indexes, including the Russell 2000, and filed a US$161.7 million ESOP shelf registration. This shift, alongside the appointment of a new CFO, could change its institutional ownership and trading patterns, and investors will be looking at how the company confronts persistent top-line weakness and works to stabilize sales and margins. Despite recent revenue softness, the company's digital dentistry push and cost actions are key to its investment narrative, with projections of $3.8 billion revenue by 2029.
DENTSPLY SIRONA : PDS Health Surpasses Five Million CEREC Chairside Restorations with Dentsply Sirona, Marking a Major Milestone in Scaled Digital Dentistry
PDS Health, in collaboration with Dentsply Sirona, has achieved a significant milestone by completing over five million CEREC chairside restorations. This accomplishment highlights PDS Health's extensive adoption of digital dentistry, with over 1,200 CEREC systems installed, enabling efficient, high-quality, and same-day restorative care for millions of patients. The partnership underscores a shared commitment to advancing digital dental technologies, improving clinical workflows, and enhancing the patient experience.
Dentsply Sirona and HeyGears expand digital denture collaboration to one-piece production with Lucitone
Dentsply Sirona and HeyGears have expanded their digital denture collaboration by validating a workflow for one-piece denture production using Lucitone Digital Print Denture resins and HeyGears' UltraCraft MMF 3D printer. This innovation allows dental laboratories to print dentures in a single, more efficient process, eliminating the need for separate bonding of teeth to denture bases. The companies emphasize that this streamlined workflow enhances durability, aesthetics, and performance, making advanced digital denture manufacturing more accessible to laboratories.
Precision Trading with Dentsply Sirona Inc. (XRAY) Risk Zones
This article provides a precision trading analysis for Dentsply Sirona Inc. (XRAY), highlighting a strong near and mid-term sentiment despite a weak long-term outlook. It details specific trading strategies—position, momentum breakout, and risk hedging—with entry zones, targets, and stop losses, based on AI-generated signals and multi-timeframe analysis. The analysis emphasizes an exceptional 55.3:1 risk-reward setup, targeting a 15.8% gain versus 0.3% risk.
DENTSPLY SIRONA Inc.(NasdaqGS: XRAY) dropped from Russell 1000 Index
DENTSPLY SIRONA Inc. (NasdaqGS: XRAY) has been removed from the Russell 1000 Index. This news follows several other recent announcements from the company, including the appointment of John Fortson as CFO and expansions of their distribution network for dental solutions. The company also recently reported its Q1 2026 earnings.
DENTSPLY SIRONA Inc.(NasdaqGS: XRAY) dropped from Russell 1000 Value Benchmark
DENTSPLY SIRONA Inc. (NasdaqGS: XRAY) has been removed from the Russell 1000 Value Benchmark. This update was reported on June 29, 2026, by S&P Capital IQ. The company manufactures professional dental products and technologies, including solutions for dental and oral health, and other medical devices.
DENTSPLY SIRONA Inc.(NasdaqGS: XRAY) added to Russell 2000 Index
DENTSPLY SIRONA Inc. (NasdaqGS: XRAY), a diversified manufacturer of professional dental products and technologies, has been added to the Russell 2000 Index. The article also provides recent news regarding the company, including the appointment of John Fortson as CFO and updates on their distribution partnerships and earnings results.
DENTSPLY SIRONA Inc.(NasdaqGS:XRAY) dropped from Russell Midcap Value Benchmark
DENTSPLY SIRONA Inc. (NasdaqGS:XRAY) has been removed from the Russell Midcap Value Benchmark. The announcement was made by S&P Capital IQ and published on June 29, 2026. This news comes amidst other recent updates for the company, including executive appointments, earnings reports, and distribution network expansions.
iCAT and BluePort Legal launch UPC battle against dental tech giant Dentsply
Japanese software manufacturer iCAT has filed an infringement claim against Dentsply Sirona at the Unified Patent Court (UPC) in Mannheim, Germany. The lawsuit concerns iCAT's expired patent EP 1808129, covering software for planning dental implants, and seeks damages for past use of the technology. This case marks BluePort Legal's UPC debut and highlights increasing patent disputes in the lucrative dental technology market.
DENTSPLY SIRONA Inc.(NasdaqGS: XRAY) added to Russell 2000 Value Benchmark
DENTSPLY SIRONA Inc. (NasdaqGS: XRAY), a diversified manufacturer of professional dental products, has been added to the Russell 2000 Value Benchmark. The company's stock trades on NasdaqGS under the ticker XRAY. This inclusion indicates recognition within the value investment segment of the market.
DENTSPLY SIRONA Inc.(NasdaqGS: XRAY) dropped from Russell 1000 Dynamic Index
DENTSPLY SIRONA Inc. (NasdaqGS: XRAY), a diversified manufacturer of professional dental products, has been removed from the Russell 1000 Dynamic Index. This news follows several recent announcements from the company, including the appointment of John C. Fortson as its new CFO and executive vice president, effective July 20, 2026. The company also recently reported its Q1 2026 earnings, maintaining its earnings guidance for the year.
Price to sales forward of DENTSPLY SIRONA Inc. – NASDAQ:XRAY
The article focuses solely on the "Price to sales forward" metric for DENTSPLY SIRONA Inc. (NASDAQ: XRAY). It presents this financial data point within the context of the company's TradingView profile, indicating its availability for market analysis. No further details or analysis regarding the metric's value, changes, or implications are provided in the content.
DENTSPLY SIRONA, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh Actuals & Estimates (BMFBOVESPA:XRAY34) — TradingView
This page provides an overview of DENTSPLY SIRONA, Inc. (BMFBOVESPA:XRAY34) for investors, focusing on financial actuals and estimates. It allows users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform emphasizes the importance of due diligence, stating it is not investment advice.
Enterprise value to revenue forward of DENTSPLY SIRONA Inc. – NASDAQ:XRAY
This article briefly mentions the enterprise value to revenue forward for DENTSPLY SIRONA Inc. (NASDAQ: XRAY). It appears to be a stub or a placeholder page from TradingView, providing financial context for the company's NASDAQ listing.
DENTSPLY SIRONA, Inc. Actuals & Estimates (NASDAQ:XRAY)
This article provides current and estimated financial data for DENTSPLY SIRONA Inc. (NASDAQ: XRAY), including its stock price, market capitalization, earnings, revenue, and dividend information. It also includes analyst forecasts for the stock's future price and frequently asked questions about its performance and history.
Enterprise value to revenue forward of DENTSPLY SIRONA, Inc. – FWB:DY2
This page from TradingView provides financial information for DENTSPLY SIRONA, Inc. (FWB:DY2) on the Frankfurt Stock Exchange. It specifically highlights the company's enterprise value to revenue forward metric. The content indicates that the market is currently closed with no trades recorded.
Enterprise value to EBIT forward of DENTSPLY SIRONA Inc. – NASDAQ:XRAY
This article displays the forward Enterprise Value to EBIT ratio for DENTSPLY SIRONA Inc. (NASDAQ: XRAY) on TradingView. It indicates that the market was closed at the time of viewing, with no trades reported. The content is primarily a data point presentation from TradingView's financial section for the company.
XRAY Technical Analysis & Stock Price Forecast
This article provides a technical analysis of DENTSPLY SIRONA Inc (XRAY), indicating an overall "Sell" consensus based on various technical indicators and moving averages. While some short-term moving averages suggest a "Buy", longer-term averages and key oscillators like MACD point to a "Sell" signal. The stock is currently trading below its 60-day and 200-day moving averages, with key support at $9.695 and resistance at $10.925.
Price to earnings forward of DENTSPLY SIRONA Inc. – NASDAQ:XRAY
The provided content is a fragment from a TradingView page for DENTSPLY SIRONA Inc. (NASDAQ: XRAY). It lists navigation elements, market data providers, and copyright information, but lacks specific financial data about the company's price-to-earnings forward ratio. The article primarily details the website's structure and legal disclaimers.
How Investors May Respond To DENTSPLY SIRONA (XRAY) Appointing John C. Fortson As CFO And EVP
DENTSPLY SIRONA has appointed John C. Fortson as EVP and CFO, effective July 20, 2026. Fortson's extensive financial and operational background could significantly influence the company's capital allocation and its efforts to achieve consistent, profitable growth amid ongoing revenue pressures and restructuring. Investors will be watching to see how his experience helps translate transformation plans into tangible results and whether it alters the company's financial guidance.
DENTSPLY SIRONA (XRAY) Stock Could Be 78% Undervalued After CFO Appointment
DENTSPLY SIRONA (XRAY) is back in focus after appointing John C. Fortson as CFO and Executive Vice President, a change that could influence investor perception. Despite recent share price declines, the stock is considered 78% undervalued by one narrative, suggesting a fair value of $45.50 compared to its current price of $10.03, based on recurring dental demand and resilient margins. Investors are encouraged to review figures and evaluate potential upsides, especially given the company's current loss-making status.
Dentsply Sirona director Jonathan Mazelsky buys $101,400 in shares
Jonathan Jay Mazelsky, a director at DENTSPLY SIRONA Inc. (NASDAQ:XRAY), recently purchased 10,000 shares of the company's common stock for $101,400. This open market purchase comes as the stock trades near its 52-week low and offers a 6.2% dividend yield. The company also reported mixed Q1 2026 financial results with revenue beating expectations but EPS falling short, alongside an expanded distribution agreement.
Dentsply Sirona (XRAY) SVP details stock, RSU, phantom and option holdings
Dentsply Sirona Inc.'s SVP, GC & Secretary, Lindi Rene Barton-Brobst, filed an initial statement of beneficial ownership (Form 3) detailing her holdings. The filing shows direct ownership of 45,185.444 shares of common stock, including 38,743.444 Restricted Stock Units, and 254.6498 indirectly held shares in a 401(k) plan. She also holds phantom stock units and multiple stock options with varying exercise prices and expiration dates, none of which indicate recent buying or selling activity.
Dentsply Sirona director Jonathan Mazelsky buys $101,400 in shares
Dentsply Sirona director Jonathan Mazelsky recently purchased 10,000 shares of the company's common stock for $10.14 per share, totaling $101,400. This transaction occurred while the stock is near its 52-week low, and InvestingPro analysis suggests the company is undervalued, offering a 6.2% dividend yield. Dentsply Sirona also reported mixed Q1 2026 financial results with revenue beating expectations but EPS falling short, alongside an expanded distribution agreement.
Dentsply Sirona (XRAY) director amends Form 4 to show share purchase
Dentsply Sirona director Jonathan Jay Mazelsky filed an amended insider report (Form 4/A) to clarify a prior transaction. The amendment specifies that his purchase of 10,000 shares of common stock at $10.14 per share was an open-market acquisition, correcting an earlier mistaken report that coded it as an award. Following this transaction, Mazelsky's direct ownership in Dentsply Sirona now totals 61,668.534 shares.
Dentsply Sirona director Clyde Hosein buys $64,902 in common stock
Clyde Hosein, a director at Dentsply Sirona Inc. (NASDAQ:XRAY), purchased 6,500 shares of the company’s common stock for $64,902. This transaction, made at $9.985 per share, increases Hosein's direct holdings to 70,575.456 shares. The stock is currently trading near its 52-week low, and InvestingPro analysis suggests it is undervalued with significant upside potential, offering a 6.12% dividend yield.
Insider Buying: Clyde Hosein Acquires Shares of Dentsply Sirona Inc (XRAY)
Clyde Hosein, a Director at Dentsply Sirona Inc (XRAY), recently purchased 6,500 shares, bringing his total ownership to 70,575.456 shares. This transaction follows a pattern of 10 insider buys against 1 insider sell over the past year, indicating confidence in the company. Although the stock is trading at $9.99 with a market cap of $2.093 billion, its GF Value of $19.08 suggests it might be a "Possible Value Trap, Think Twice."
Director Clyde Hosein buys 6,500 DENTSPLY SIRONA (XRAY) shares at $9.985
DENTSPLY SIRONA Inc. director Clyde Hosein recently purchased 6,500 shares of common stock at $9.985 per share through an open-market transaction. This purchase increases his direct ownership in the company to 70,575.456 shares, signaling a higher personal equity stake. The transaction was disclosed via a Form 4 filing with the SEC.
Dentsply Sirona director McKeon buys $101,199 in company stock
Dentsply Sirona director Brian P. McKeon recently purchased 10,000 shares of the company's common stock for over $101,000. This insider acquisition comes as the stock trades near its 52-week low and is considered undervalued by InvestingPro analysis, offering a significant 6.34% dividend yield. The company also announced mixed Q1 2026 results with revenue beating expectations but EPS falling slightly short, alongside an expanded partnership with Nashville Dental.
Dentsply Sirona director Brian Gladden buys $100k in stock
Dentsply Sirona director Brian T. Gladden purchased approximately $100,000 worth of company common stock on June 15, 2026, acquiring over 9,900 shares at prices around $10.01. This transaction occurred while the stock is near its 52-week low and is considered undervalued by InvestingPro. The company recently reported mixed first-quarter 2026 results, exceeding revenue expectations but slightly missing on EPS, and announced an expanded distribution partnership.
Dentsply Sirona director Brian Gladden buys $100k in stock By Investing.com
Dentsply Sirona director Brian Gladden purchased approximately $100,000 worth of common stock, acquiring 9,985.022 shares at prices around $10.015 per share. This transaction occurred on June 15, 2026, with the stock trading near its 52-week low. The company has a 32-year dividend payment history and recently reported mixed Q1 2026 results and an expanded distribution partnership.
Director at DENTSPLY SIRONA (XRAY) receives 10,000-share stock award
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky was granted 10,000 shares of common stock on June 12, 2026, valued at $10.14 per share, as reported in a Form 4 SEC filing. This award increased his direct holdings in the company to 61,668.534 shares. The transaction was a compensation-related grant rather than an open-market purchase.
Director Brian P. McKeon adds 10,000 DENTSPLY SIRONA (XRAY) shares via trust purchase
DENTSPLY SIRONA Inc. director Brian P. McKeon, through a trust, purchased 10,000 shares of the company's common stock at $10.12 per share on June 12, 2026. This open-market transaction represents an indirect ownership acquisition. Following this purchase, McKeon directly holds 28,887 common shares, and the trust holds 10,000 shares indirectly.
Dentsply Sirona names John Fortson as new finance chief
Dentsply Sirona has appointed John Fortson as its new executive vice president and chief financial officer, effective July 20. Fortson brings over 25 years of experience in finance and operations, including previous CFO and CEO roles. His appointment aims to strengthen the company's financial discipline and drive its return-to-growth strategy, following a period of net losses.
How DENTSPLY SIRONA’s New Veteran CFO Could Shape Capital Allocation and Strategy for XRAY Investors
DENTSPLY SIRONA has appointed John C. Fortson as its new CFO, a move that could significantly influence the company's capital allocation and operational strategy. Fortson’s extensive experience in complex manufacturing and finance is seen as crucial for DENTSPLY SIRONA to achieve its reaffirmed 2026 net sales guidance amidst recent losses and weak sales performance. Investors will closely watch how his leadership impacts the company's financial discipline and execution, especially given existing market challenges.
Dentsply Sirona Appoints John Fortson as New CFO
Dentsply Sirona has appointed John C. Fortson as executive vice president and chief financial officer, effective July 20, 2026. Fortson brings over 25 years of experience in finance, operations, and strategy, with the aim to bolster Dentsply Sirona's financial leadership and support its Return-to-Growth Action Plan. His compensation package includes a $780,000 base salary, performance bonuses, and equity awards, reflecting the strategic importance of the role to the company's long-term growth.
Dentsply Sirona Appoints John Fortson as Chief Financial Officer
Dentsply Sirona (Nasdaq: XRAY) has announced the appointment of John Fortson as Executive Vice President and Chief Financial Officer, effective July 20. Fortson brings over 25 years of leadership experience in finance, operations, and strategy, including previous roles as CFO and CEO of global manufacturing businesses. His appointment is expected to help advance Dentsply Sirona's "Return-to-Growth Action Plan" and drive long-term value for shareholders.
Dentsply Sirona appoints John Fortson as CFO
This article announces that Dentsply Sirona has appointed John Fortson as its new Chief Financial Officer. Fortson brings experience to the role, which is a key leadership position within the company.
Press Release: Dentsply Sirona Appoints John Fortson as Chief Financial Officer
Dentsply Sirona has announced the appointment of John Fortson as its new Chief Financial Officer, effective immediately. Fortson brings extensive financial leadership experience to the company, having previously served as CFO for various publicly traded companies. This strategic hire is expected to strengthen Dentsply Sirona's financial leadership team and support its future growth initiatives.
Dentsply Sirona appoints new CFO
Dentsply Sirona has appointed John Fortson, former CFO of Kymera International, as its new CFO, effective July 20. Fortson brings over two decades of finance experience and will focus on advancing the company's return-to-growth plan after recent leadership turnover and an accounting probe. His compensation package includes an annual base salary of $780,000, a $500,000 signing bonus, and equity awards.
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now
DENTSPLY SIRONA (XRAY) is positioned for growth due to its "Return-to-Growth" strategy, distribution
Dentsply Sirona Appoints John Fortson as Chief Financial Officer
Dentsply Sirona (Nasdaq: XRAY) has appointed John Fortson as Executive Vice President and Chief Financial Officer, effective July 20. Fortson brings over 25 years of experience in finance, operations, and strategy, including previous roles as CFO and CEO of global manufacturing businesses. His appointment is expected to strengthen financial discipline, drive growth, and enhance shareholder returns as the company focuses on its "Return-to-Growth Action Plan."
Dentsply Sirona (XRAY) Appoints John Fortson as CFO
Dentsply Sirona (XRAY) has announced the appointment of John Fortson as its new Executive Vice President and Chief Financial Officer, effective July 20, 2026. Fortson brings extensive experience from previous executive roles at Kymera International and Ingevity. The company's GF Score™ is 56/100, indicating moderate potential for long-term returns, but highlights concerns in financial strength and growth, suggesting investors should proceed with caution despite the new CFO appointment.
Veteran finance leader John Fortson named CFO at Dentsply Sirona (NASDAQ: XRAY)
Dentsply Sirona (NASDAQ: XRAY) has appointed John C. Fortson as Executive Vice President and Chief Financial Officer, effective July 20, 2026. Fortson brings over 25 years of leadership experience in finance, operations, and strategy from global manufacturing and industrial businesses, including CEO and CFO roles at Ingevity Corporation and Kymera International. His compensation package includes a $780,000 annual base salary, significant bonuses, and equity awards, reflecting a robust incentive structure.
